Exelixis, Inc. (EXEL) - Form 10-Q Summary
Business Context and Reporting Period
Company: Exelixis, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2002
Business Overview: Exelixis is a biotechnology company focused on developing proprietary human therapeutics, primarily in cancer, using comparative genomics and model system genetics. The company generates revenue through collaborative research agreements, license fees, and government grants.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2002 |
6 Months Ended June 30, 2002 |
6 Months Ended June 30, 2001 |
|---|---|---|---|
| Total Revenues | $9,897 | $21,439 | $16,285 |
| Net Loss | $(23,904) | $(42,324) | $(36,427) |
| Loss Per Share (Basic & Diluted) | $(0.43) | $(0.76) | $(0.81) |
| Operating Cash Flow | N/A | $(50,561) | $(15,381) |
| Cash & Cash Equivalents | $5,793 | $5,793 | $46,063 |
| Short-term Investments | $165,456 | $165,456 | $192,116 |
| Total Liquidity (Cash + ST Inv) | $171,249 | $171,249 | $238,179 |
| Long-term Debt (Notes & Leases) | $41,601 | $41,601 | $31,996 |
Note: Figures are in thousands. Total liquidity includes cash, cash equivalents, and short-term investments.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 16% year-over-year for the six-month period ($21.4M vs. $16.3M), driven by new collaborations with Protein Design Labs and Bristol-Myers Squibb, and compound deliveries under chemistry collaborations.
- Increased Expenses: Research and Development (R&D) expenses rose significantly to $55.4M for the six months ended June 30, 2002, compared to $37.4M in 2001. This 48% increase was due to higher personnel costs (49% increase), lab supplies (79% increase), and licensing/consulting fees (104% increase).
- Cash Position: Cash and cash equivalents decreased from $35.6M at year-end 2001 to $5.8M at June 30, 2002. Total liquidity (including short-term investments) declined from $227.7M to $171.2M due to operating cash burn and restricted cash allocations.
- Accounting Changes: The company adopted SFAS No. 142 on January 1, 2002, discontinuing the amortization of goodwill. This reduced amortization expenses significantly compared to 2001.
- Discontinued Operations: The Genomica software business was transferred to Visualize, Inc. in April 2002. Results are reported as discontinued operations, including a $0.97M goodwill write-off.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur additional operating losses for the foreseeable future. They anticipate current cash and investments will fund operations for at least the next two years, though additional financing may be required.
- Development Pipeline: The company is advancing a rebeccamycin analogue (Phase II trials) and preparing to file its first proprietary Investigational New Drug (IND) application, potentially in the first quarter of 2003.
- Collaboration Risks: Revenue is heavily dependent on collaborations (e.g., Bayer, Bristol-Myers Squibb). The termination of the Pharmacia collaboration in February 2002 eliminated approximately $9.0M in expected annual revenue.
- Capital Needs: The company lacks manufacturing capabilities for clinical trials and relies on third parties. Failure to secure additional capital or favorable terms for financing could force a curtailment of operations.
- Regulatory Risks: Potential products face lengthy and uncertain regulatory approval processes. Clinical trials may fail to demonstrate safety or efficacy.
Key Facts for Investor Verification
- Liquidity Runway: Verify the sufficiency of the $171.2M liquidity position against the $50.6M operating cash burn in the first half of 2002 to confirm the "two-year" runway estimate.
- Collaboration Renewals: Monitor the status of the Bristol-Myers Squibb mechanism of action agreement (expiring September 2002) and the impact of the Bayer acquisition of Aventis on the Agrinomics joint venture.
- IND Filing Timeline: Track progress on the proprietary IND filing, targeted for Q1 2003, as a critical milestone for future revenue potential.
- Debt Covenants: Review the terms of the $16.0M equipment line of credit (May 2002) and the $30.0M convertible promissory note to understand refinancing risks and interest obligations.
- Stock Compensation: Note the significant decrease in stock compensation expense in 2002 due to accounting method changes and market value fluctuations, which may not be sustainable.